Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy (Q56979020)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30289966%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

title

Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30289966%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

main subject

Salivary duct carcinoma

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30289966%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Yohitsugu Mitani

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30289966%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Renata Ferrarotto

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30289966%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

6

Randal S Weber

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30289966%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

author name string

Kristen B Pytynia

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30289966%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Dianna B Roberts

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30289966%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Merrill S Kies

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30289966%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Sankar N Maity

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30289966%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Sue-Hwa Lin

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30289966%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Adel K El-Naggar

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30289966%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

language of work or name

English

0 references

publication date

1 September 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30289966%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30289966%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

volume

124

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30289966%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

issue

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30289966%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

page(s)

3693-3705

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30289966%20AND%20SRC:MED&resulttype=core&format=json

Salivary duct carcinoma: what is already known, and can we improve survival?

26 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

Salivary duct carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

Salivary duct carcinoma. Part I. A clinicopathologic evaluation and DNA image analysis of 13 cases with review of the literature

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

Mucin-rich variant of salivary duct carcinoma: a clinicopathologic and immunohistochemical study of four cases.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

Primary mucin-producing tumours of the salivary glands: a clinicopathological and morphometric study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

Systemic therapy in the palliative management of advanced salivary gland cancers.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

Salivary gland tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

HER2 expression in salivary gland carcinomas: dependence on histological subtype.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

Differential expression of hormonal and growth factor receptors in salivary duct carcinomas: biologic significance and potential role in therapeutic stratification of patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

PIK3CA mutations and PTEN loss in salivary duct carcinomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

EGFR and HER2-Akt-mTOR signaling pathways are activated in subgroups of salivary gland carcinomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

Comprehensive molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

Current development of mTOR inhibitors as anticancer agents

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

Challenges in the clinical development of PI3K inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

The functions and regulation of the PTEN tumour suppressor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: potential therapeutic ramifications.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

Nonsyntenic amplification of MYC with CDK4 and MDM2 in a malignant mixed tumor of salivary gland

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

Chromosomal abnormalities and molecular landscape of metastasizing mucinous salivary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

A mucin-rich variant of salivary duct carcinoma with a prominent mucinous component, a tumor that mimics mucinous adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

Salivary duct carcinoma: targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

PTEN-deficient cancers depend on PIK3CB.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

Cancer biomarkers: selecting the right drug for the right patient

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

The cancer biomarker problem

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

PTEN and the PI3-kinase pathway in cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

PTEN loss in the continuum of common cancers, rare syndromes and mouse models.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

PI3K pathway alterations in cancer: variations on a theme

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

PI(3)king apart PTEN's role in cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

https://api.crossref.org/works/10.1002%2FCNCR.31600

1 reference

7 January 2021

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

Subsets of salivary duct carcinoma defined by morphologic evidence of pleomorphic adenoma, PLAG1 or HMGA2 rearrangements, and common genetic alterations.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

High frequency of mutations of the PIK3CA gene in human cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

Integrative genomic profiling of human prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

The PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, cross-talk, and therapies.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

Targeting PI3K signaling as a therapeutic approach for colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

Mutational heterogeneity in cancer and the search for new cancer-associated genes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

Spatio-Temporal Genomic Heterogeneity, Phylogeny, and Metastatic Evolution in Salivary Adenoid Cystic Carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

Breaking up is hard to do: PI3K isoforms on the rebound.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

Somatic mutations in salivary duct carcinoma and potential therapeutic targets.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

Trastuzumab for the treatment of salivary duct carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31600

7 January 2021

Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment?

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/30289966

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1002/CNCR.31600

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30289966%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30289966%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

1 reference